NCT05494697View on ClinicalTrials.gov

Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC

PHASE2SuspendedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

December 31, 2029

Study Completion Date

January 31, 2030

Conditions
Pancreatic Cancer
Interventions
DRUG

Rintatolimod

Rintatolimod (poly I : poly C12U)

Trial Locations (3)

44718

Gabrail Cancer Center Research, Canton

68198

Nebraska Medical Center, Omaha

98101

Virginia Mason Medical Center, Seattle

Sponsors

Collaborators (1)

Amarex Clinical Research
All Listed Sponsors
collaborator

Amarex Clinical Research

OTHER

lead

AIM ImmunoTech Inc.

INDUSTRY